Abstract
Methods The stability of CAST was monitored throughout the study using reversed phase high performance liquid chromatography. CAST or placebo capsules were administered to 33 DN subjects, in a randomized double-blind, placebocontrolled study. The dose of CAST was escalated from 60 mg to 240 mg/day over the first 12 weeks, followed by a stable dose of 240 mg/day for the remaining 40 weeks. The primary outcome was total symptom score (TSS), while secondary outcomes were nerve conduction studies, neurological disability score (NDS) and qualitative sensory testing (QST).
Highlights
The Ayurvedic nerve tonic herb Centella asiatica demonstrates potential neuro-regenerative properties in in vitro and in vivo models
The stability of CAST was monitored throughout the study using reversed phase high performance liquid chromatography
CAST or placebo capsules were administered to 33 diabetic neuropathy (DN) subjects, in a randomized double-blind, placebocontrolled study
Summary
The aims of the present study were to evaluate the safety and therapeutic effects of CAST (Indena®, Milan, Italy) in humans with DN, while monitoring the stability of CAST during the trial period
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
